Leah Melton, APRN
Nurse Practitioner · Norman, OKNPI 1679824601
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $75,934 of the $87,363 with a category attached, or 86.9%. Novo Nordisk accounts for 80.2% of it on its own, with 26 other manufacturers making up the rest. 2025 is the largest year on record at $32,439, 3.5 times the $9,174 reported in 2021. Among nurse practitioner clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 425 payments — averaging $205.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$70K
- Xeris Pharmaceuticals, Inc.$6K
- Tandem Diabetes Care, Inc.$4K
- Mannkind Corporation$3K
- Corcept Therapeutics$571
- Boehringer Ingelheim$504
- plus $3K from 21 others
What the payments were for
- Speaking & faculty fees$75,93487%
- Travel & lodging$3,5834%
- Food & beverage$7,7679%
- Education$200%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 129 | $70,067 |
| Xeris Pharmaceuticals, Inc. | 36 | $6,295 |
| Tandem Diabetes Care, Inc. | 23 | $4,137 |
| Mannkind Corporation | 40 | $2,684 |
| Corcept Therapeutics | 27 | $571 |
| Boehringer Ingelheim | 32 | $504 |
| Zealand Pharma US, Inc. | 2 | $488 |
| AstraZeneca | 13 | $468 |
| Lilly USA, LLC | 18 | $380 |
| Vistapharm, Inc. | 42 | $375 |
| Sanofi-aventis U.S. LLC | 6 | $331 |
| Insulet Corporation | 17 | $299 |
| Ascensia Diabetes Care US Inc. | 7 | $150 |
| BETA Bionics, Inc. | 4 | $84 |
| Amarin Pharma, Inc. | 5 | $80 |
| Bayer | 4 | $78 |
| Dexcom, Inc. | 3 | $69 |
| Cequr Corporation | 2 | $60 |
| Abbott | 3 | $51 |
| Sequel Med Tech, LLC | 2 | $42 |
| Medtronic | 2 | $34 |
| Amgen | 2 | $29 |
| Amphastar Pharmaceuticals, Inc. | 2 | $29 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$34,880
- RYBELSUS$29,169
- GVOKE HYPOPEN$5,715
- t:slim X2 Insulin Pump with Control-IQ$3,900
- AFREZZA$2,035
- ZEGALOGUE$475
- SOLIQUA 100/33$243
- FARXIGA$124
- Korlym$108
How this compares
$87,363 in reported general payments places this provider in the 95th percentile of 824 nurse practitioner providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 256 | $430,407 |
| OzempicSemaglutide | 141 | $216,895 |
| Tresiba Flextouch U-200Insulin Degludec | 52 | $85,556 |
| TrulicityDulaglutide | 47 | $80,072 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 37 | $78,832 |
| JardianceEmpagliflozin | 61 | $71,166 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $67,521 |
| FarxigaDapagliflozin Propanediol | 40 | $39,456 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 12 | $32,167 |
| NovologInsulin Aspart | 47 | $29,608 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $25,582 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 15 | $24,068 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 14 | $19,073 |
| HumalogInsulin Lispro | 32 | $18,632 |
| JanuviaSitagliptin Phosphate | 19 | $17,212 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $380 | $529,111335 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Novolog | $70,067 | $278,670200 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $504 | $90,23975 claims |
| AstraZenecaFarxiga | $468 | $39,45640 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $331 | $25,58211 claims |
| MerckJanuvia | $13 | $17,21219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 824 nurse practitioner providers in Oklahoma.
Other nurse practitioner in Norman
- Monica LawsonNorman$15K
- Krupa MathewNorman$13K
- Donnell HammonsNorman$9K
- Susan ThompsonNorman$8K
- Jeneice MillerNorman$6K
- Brenda JamesNorman$5K
- Jenny GuthrieTulsa$106K
- Sara GoreOklahoma City$52K
- Teisha GalleglyMoore$43K
- Stacy NewberryTulsa$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.